MediciNova Stock Discussion

$MediciNova(MNOV.US)$ Reuters· 2 mins ago
Medicinova Receives Notice of Allowance for New Patent Covering Mn-166 (Ibudilast) for the Prevention of Metastasis of Various Solid Cancer

$MediciNova(MNOV.US)$ Medicinova Announces Data From Phase 1B/2a Clinical Trial of Mn-166 (Ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (Asco) Annual Meeting 2024. Was safe and well tolerated.

$MediciNova(MNOV.US)$
MediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic Conditions
MediciNova announced two poster presentations at the 92nd European Atherosclerosis Society (EAS) 2024 Congress. The presentations highlighted the efficacy, safety, and tolerability of MN-001 (Tipelukast) for non-alcoholic fatty liver disease (NAFLD) and its metaboli...

$MediciNova(MNOV.US)$ Reuters· 1 min ago
Medicinova - Gets Notice of Allowance for New Patent Covering Mn-166 (Ibudilast) for Treating Chlorine-Induced Acute Respiratory Distress Syndrome

$MediciNova(MNOV.US)$
NEWS
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome

$MediciNova(MNOV.US)$ Reuters· 3 mins ago
Medicinova Receives Issue Notification for New Patent Covering Extended-Release Formulations of Mn-166 (Ibudilast)

$MediciNova(MNOV.US)$ MediciNova Gets Patent in Japan for Multiple Sclerosis-Related Treatment
WSJ· 2 mins ago

$MediciNova(MNOV.US)$Moomoo 24/7
MediciNova Secures Notice Of Grant For New Patent Covering MN-166 (Ibudilast) For Treatment Of Macular Injury In China

$MediciNova(MNOV.US)$Moomoo 24/7· 2 mins ago MediciNova Receives Notice Of Decision To Grant For New Patent Covering MN-166 (Ibudilast) For Treatment Of Progressive MS In Europe

$MediciNova(MNOV.US)$ phase 2 news hmmm